Literature DB >> 24610671

Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

F Marra1, B Cairns, P Jewesson.   

Abstract

The recent increase in the use of vancomycin has led to renewed interest in its pharmacokinetics, and, in particular, the importance of monitoring serum drug concentrations. A review of the literature and evaluation of pharmacokinetic data from Vancouver Hospital and Health Sciences Centre demonstrated that vancomycin meets the criteria necessary for serum drug concentration monitoring. These include the availability of a sensitive and specific assay, substantial interpatient and intrapatient variability in drug disposition, and evidence suggesting a correlation between vancomycin serum concentration and both efficacy and toxicity. A review of vancomycin disposition data for 371 consecutive treatment courses at this hospital revealed significant interpatient variability in drug clearance and volume of distribution. Accordingly, it would be difficult to accurately predict the change in serum concentration resulting from a given vancomycin dose. There appears to be less intrapatient variability in volume of distribution; however, serum elimination half-life tends to increase during treatment, necessitating an alteration in dose interval. Although convenient, physiological parameters to monitor serum creatinine concentration and bodyweight are not accurate predictors of drug clearance and volume of distribution. Serum concentration monitoring is also necessary to ensure that vancomycin concentrations are in excess of the minimum inhibitory concentration of the organism at all times during treatment. Although a causal relationship between vancomycin and toxicity has been difficult to prove, there is some evidence in the literature to support a relationship between high troughs and nephrotoxicity. In view of the available evidence, we do not believe that serum concentration monitoring should be totally abandoned. We have created empiric dosage guidelines and a decision-making algorithm for serum drug concentration monitoring that have streamlined the process of drug prescribing and monitoring at this institution.

Entities:  

Year:  1996        PMID: 24610671     DOI: 10.2165/00044011-199612020-00006

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  73 in total

1.  Once-daily aminoglycoside dosing: A new look at an old drug.

Authors:  J Conly; W Gold; S Shafran
Journal:  Can J Infect Dis       Date:  1994-09

2.  Evaluation of a method for initiating vancomycin therapy: experience in 205 patients.

Authors:  K D Lake; C D Peterson
Journal:  Pharmacotherapy       Date:  1988       Impact factor: 4.705

3.  Routine monitoring of serum vancomycin concentrations: waiting for proof of its value.

Authors:  D J Edwards; S Pancorbo
Journal:  Clin Pharm       Date:  1987-08

4.  Routine monitoring of serum vancomycin concentrations: can waiting be justified?

Authors:  K A Rodvold; H Zokufa; J C Rotschafer
Journal:  Clin Pharm       Date:  1987-08

Review 5.  Vancomycin: an update.

Authors:  R P Cheung; J T DiPiro
Journal:  Pharmacotherapy       Date:  1986 Jul-Aug       Impact factor: 4.705

6.  The clinical pharmacology of vancomycin in seriously ill preterm infants.

Authors:  M D Reed; R M Kliegman; J S Weiner; M Huang; T S Yamashita; J L Blumer
Journal:  Pediatr Res       Date:  1987-09       Impact factor: 3.756

7.  Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci.

Authors:  C U Tuazon; H Miller
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

8.  Vancomycin pharmacokinetics in small, seriously ill infants.

Authors:  S H Naqvi; W J Keenan; R M Reichley; K P Fortune
Journal:  Am J Dis Child       Date:  1986-02

9.  Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function.

Authors:  R C Moellering; D J Krogstad; D J Greenblatt
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

10.  Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia.

Authors:  A E Zimmermann; B G Katona; K I Plaisance
Journal:  Pharmacotherapy       Date:  1995 Jan-Feb       Impact factor: 4.705

View more
  5 in total

Review 1.  Therapeutic drug monitoring: do the improved outcomes justify the costs?

Authors:  G E Schumacher; J T Barr
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Development and validation of a novel vancomycin dosing nomogram for achieving high-target trough levels at 2 canadian teaching hospitals.

Authors:  Rosanne Thalakada; Michael Legal; Tim T Y Lau; Tiffany Luey; Josh Batterink; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2012-05

Review 4.  Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

Authors:  Richard S Slavik; Peter J Jewesson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Vancomycin Pharmacokinetic Parameters in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT).

Authors:  Maryam Taghizadeh Ghehi; Saeed Rezaee; Alireza Hayatshahi; Molouk Hadjibabaie; Kheirollah Gholami; Mohammadreza Javadi; Seyed Hamid Khoee; Mania Radfar; Mohsen Esfandbod; Ardeshir Ghavamzadeh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2013
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.